Supplementary Figures S1-S30 from Multidimensional Characterization of Tumor–Immune Architecture Reveals Clinically Relevant Classic Hodgkin Lymphoma Subtypes

Authors:
Open Access
Publisher website
Google Scholar
Abstract
Figure S1. Co-occurrence of mutation in CHL. Figure S2. STAT6 copy number gain. Figure S3. Frequent mutations according to key clinical features. Figure S4. Copy number alterations according to EB Virus (EBV) status on HRS cells. Figure S5. Multivariable analyses on thymic mutation. Figure S6. Coding mutation count according to key clinical features in CHL. Figure S7. Impact of molecular profile on survival in CHL. Figure S8. STAT6 mutations in CHL. Figure S9. Impact of molecular profile on survival in elderly CHL. Figure S10. MHC status on HRS cells and their molecular correlates. Figure S11. Molecular Subgroups of CHL. Figure S12. Correlation between molecular subtypes and key clinical features. Figure S13. Molecular subtype and progression free survival (PFS) in Hodgkin lymphoma. Figure S14. Overview of the imaging mass cytometry (IMC) analysis and panel. Figure S15. Spatial tumor-microenvironment correlates with molecular subtype in CHL. Figure S16. Membrane map depicting major immune cell populations in each molecular subgroup. Figure S17. Correlation between molecular subtypes and key features. Figure S18. Evidence of CSF2RB mutant allele expression at the protein level in L-1236 KO model. Figure S19. CSF2RB mutations confer cytokine-dependent gain-of-function signaling in the L-428 model. Figure S20. CSF2RB mutations promote activation of the STAT5 signaling pathway. Figure S21. Co-expression of CSF2RB-WT and E788* mutant enhances downstream cytokine responses. Figure S22. Characterization of extrinsic phenotypes of CSF2RB mutations. Figure S23. Tumor-microenvironment characterization with molecular subtype in CHL. Figure S24. Cohort and study design overview for the HLGen development. Figure S25. Oncoplot of the CHL samples from Stanford ctDNA cohort (n = 293), with clinical annotation according to molecular subtype. Figure S26. Impact of feature list reduction on HLGen classifier performance. Figure S27. Graphical summary of molecular subtypes and their clinical and tumor-microenvironment ecosystem correlates in classic Hodgkin lymphoma. Figure S28. GeoMx analyses on CD30+ HRS cells. Figure S29. Segmentation on Imaging Mass Cytometry. Figure S30. Gating Strategy of regulatory T cell population.